Rallybio (RLYB) Set to Post Quarterly Earnings on Thursday

Key Points

• Rallybio is expected to report Q3 2026 results before market open on November 5, with analysts forecasting a loss of $1.44 per share.
• The company previously reported an EPS loss of $0.48, beating the consensus estimate by $0.96, but continues to have sharply negative profitability metrics, including a net margin of -911.07%.
• Rallybio declared a special dividend of $13.56 per share, payable November 13 to shareholders of record on November 5; analysts maintain an average “Hold” rating.

Rallybio (NASDAQ:RLYB - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.44) per share for the quarter. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Rallybio (NASDAQ:RLYB - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Rallybio Stock Up 0.4%

Shares of NASDAQ RLYB opened at $15.99 on Thursday. The firm's 50-day moving average price is $16.79 and its 200-day moving average price is $12.77. Rallybio has a 52-week low of $3.67 and a 52-week high of $17.57. The company has a market cap of $84.95 million, a PE ratio of -3.68 and a beta of -0.72.

Rallybio Announces Dividend

The business also recently disclosed a special dividend, which will be paid on Friday, November 13th. Investors of record on Thursday, November 5th will be given a dividend of $13.56 per share.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Rallybio from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Rallybio from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, Rallybio currently has an average rating of "Hold".

About Rallybio

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.

Rallybio's lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.